Ananym Urges Bio-Techne to Explore Sale After Stock Lags Life-Science Peers
Updated
Updated · Bloomberg · Jun 15
Ananym Urges Bio-Techne to Explore Sale After Stock Lags Life-Science Peers
2 articles · Updated · Bloomberg · Jun 15
Summary
Ananym Capital Management has built a stake in Bio-Techne and, in a Monday letter to the board, pressed for a strategic review that includes a potential sale.
The activist argued Bio-Techne has underperformed both life-science tools peers and the broader market, making a sale to a larger industry player more valuable than remaining independent.
A strategic review would put Bio-Techne’s standalone strategy under scrutiny and could open the door to takeover interest from bigger companies in the sector.